Literature DB >> 31394964

Non-paraneoplastic related retinopathy: clinical challenges and review.

Júlia T Takiuti1,2,3, Vitor K L Takahashi1,3,4, Christine L Xu1,3, Ruben Jauregui1,3,5, Stephen H Tsang1,3,6.   

Abstract

Autoimmune retinopathy (AIR) is a rare inflammatory condition characterized by progressive visual loss, abnormalities in visual fields and electroretinographic exams, along with presence of circulating anti-retinal antibodies. There are two main forms of AIR: paraneoplastic AIR (pAIR) and presumed non-paraneoplastic AIR (npAIR). NpAIR is considered a diagnosis of exclusion, since it is typically made after other causes of retinopathy have been investigated and the absence of malignancy is confirmed. Work-up of a npAIR case is challenging since there are no standartizaded protocols for diagnosis and treatment. The treatment regimen may vary from case to case, and it can be best guided by a set of parameters including electrophysiological responses, visual outcomes, and presence of anti-retinal antibodies. The purpose of this review is to summarize the principal clinical features, investigation, and management of npAIR.

Entities:  

Keywords:  Anti-retinal antibodies; autoimmune retinopathy; immunosuppressant; retinal antigens; treatment

Mesh:

Year:  2019        PMID: 31394964      PMCID: PMC6774818          DOI: 10.1080/13816810.2019.1650072

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  39 in total

Review 1.  The enigma of autoimmune retinopathy.

Authors:  Farzin Forooghian; Sijia Cao; Jing Cui; Joanne A Matsubara
Journal:  Int Ophthalmol Clin       Date:  2015

2.  Low titre autoantibodies against recoverin in sera of patients with small cell lung cancer but without a loss of vision.

Authors:  A V Bazhin; O N Shifrina; M S Savchenko; N K Tikhomirova; M A Goncharskaia; V A Gorbunova; I I Senin; A G Chuchalin; P P Philippov
Journal:  Lung Cancer       Date:  2001-10       Impact factor: 5.705

3.  Blindness caused by photoreceptor degeneration as a remote effect of cancer.

Authors:  R A Sawyer; J B Selhorst; L E Zimmerman; W F Hoyt
Journal:  Am J Ophthalmol       Date:  1976-05       Impact factor: 5.258

4.  Outcomes in Autoimmune Retinopathy Patients Treated With Rituximab.

Authors:  Samaneh Davoudi; Nazanin Ebrahimiadib; Cagla Yasa; Damla D Sevgi; Ramak Roohipoor; Evangelia Papavasilieou; Jason Comander; Lucia Sobrin
Journal:  Am J Ophthalmol       Date:  2017-05-05       Impact factor: 5.258

5.  Autoimmune retinopathy: patients with antirecoverin immunoreactivity and panretinal degeneration.

Authors:  J R Heckenlively; A A Fawzi; J Oversier; B L Jordan; N Aptsiauri
Journal:  Arch Ophthalmol       Date:  2000-11

Review 6.  Autoimmune retinopathy: a review and summary.

Authors:  John R Heckenlively; Henry A Ferreyra
Journal:  Semin Immunopathol       Date:  2008-04-12       Impact factor: 9.623

7.  Antirecoverin autoantibodies in the patient with non-small cell lung cancer but without cancer-associated retinopathy.

Authors:  Marina S Savchenko; Alexandr V Bazhin; Olga N Shifrina; Sofia A Demoura; Eugenia A Kogan; Alexandr G Chuchalin; Pavel P Philippov
Journal:  Lung Cancer       Date:  2003-09       Impact factor: 5.705

8.  Molecular biomarkers for autoimmune retinopathies: significance of anti-transducin-alpha autoantibodies.

Authors:  Grazyna Adamus; Lori Brown; Richard G Weleber
Journal:  Exp Mol Pathol       Date:  2009-09-08       Impact factor: 3.362

9.  Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy.

Authors:  Grazyna Adamus; Gaoying Ren; Richard G Weleber
Journal:  BMC Ophthalmol       Date:  2004-06-04       Impact factor: 2.209

Review 10.  Autoimmune retinopathy: A Review.

Authors:  Aristófanes Mendonça Canamary; Walter Yukihiko Takahashi; Juliana Maria Ferraz Sallum
Journal:  Int J Retina Vitreous       Date:  2018-01-03
View more
  1 in total

Review 1.  An update on autoimmune retinopathy.

Authors:  Parthopratim Dutta Majumder; Alessandro Marchese; Francesco Pichi; Itika Garg; Aniruddha Agarwal
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.